PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19.

Khezri, Mohammad Rafi

Khezri, Mohammad Rafi.

Khezri MR; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Sero Road, 5715799313, Urmia, Iran. Drmnkh76@gmail.com.

Hum Cell ; 34(2): 700-701, 2021 Mar.

Article in English | MEDLINE | ID: covidwho-1023370

Subject(s)

Azithromycin/therapeutic use; COVID-19 Drug Treatment; Chemotherapy, Adjuvant; Phosphatidylinositol 3-Kinases/metabolism; Proto-Oncogene Proteins c-akt/metabolism; Signal Transduction/drug effects; Antiviral Agents/therapeutic use; Azithromycin/pharmacology; COVID-19/metabolism; Humans; Inflammation Mediators/metabolism; Interleukin-6/metabolism; NF-kappa B/metabolism; Transcription Factor AP-1/metabolism; Tumor Necrosis Factor-alpha/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Signal Transduction / Chemotherapy, Adjuvant / Azithromycin / Phosphatidylinositol 3-Kinases / Proto-Oncogene Proteins c-akt / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Hum Cell Year: 2021 Document Type: Article Affiliation country: S13577-021-00484-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google